Results to be Featured in Oral Late Breaker Presentation SAN DIEGO , Nov. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that results from the company's Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH; also referred to as metabolic dysfunction associated steatohepatitis, MASH) will be highlighted in an oral late breaker presentation at the 75 th Liver Meeting ® 2024, the annual meeting of the American Association for the Study of Liver Disease (AASLD).
The Liver Meeting 2024 is being held November 15-19, 2024 , in San Diego, California . Details of the oral presentation are as follows: Title: Results from the 52-Week Phase 2b VOYAGE Trial of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis and Fibrosis: A Randomized, Placebo-Controlled Trial Presenting Author: Rohit Loomba, M.D.
, MHSc, Director, NAFLD Research Center and Professor of Medicine, University of California, San Diego Session: Late Breaking Abstract Parallel Session 3 Date/Time: Tuesday, November 19, 2024, 11:00 – 11:10 a.m. Pacific Time Location: San Diego Convention Center About VK2809 VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone be.
